GenVivo
June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
GenVivo is a private, clinical-stage company with a patented, off-the-shelf vector platform that fights cancer by activating the patient’s own immune system targeting the breadth of the patient’s own tumor antigens. GenVivo’s proprietary platform technology is a non-replicating RNA vector delivered intravenously (or intratumorally), thereby offering significant advantages versus both other vector-based and mRNA immunotherapies. GEN2, GenVivo’s lead clinical candidate now in a US Phase 1/2 clinical trial, designed to stimulate the immune system against all patient-specific tumor antigens—thereby creating a personalizing anti-tumor effect without the time delay and expense associated with some cancer vaccines, which are limited in the number of antigens delivered. GEN-1013 harnesses a potent anti-tumor cytokine delivered via our platform, which enables local expression while avoiding the systemic toxicity associated with other IL-12 therapies. The IND filing is targeted for early 2026.
Company HQ City:
San Marino
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
GEN2
CEO
David Dornsife
Year Founded
2018
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
Readout from expansion arms of GEN2 Phase 1 trial.
Approval from FDA to start Phase 1 trial with GEN-1013.
What is your next catalyst (value inflection) update?
December 2025
Website
https://genvivoinc.com/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}